Melanoma Clinical Trial
MElanoma Research Lymph Node Prediction Implementation National_001
MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
Newly diagnosed patients with invasive malignant melanoma of the skin (AJCC 8th edition staging guidelines) elected to undergo sentinel lymph node biopsy per the treating physician's recommendation.
Male or female, age ≥18 years.
Full primary melanoma pathology report unavailable.
Documented clinically apparent nodal metastases at diagnosis.
Distant metastatic disease (M1a,b,c,d) clinically present at primary diagnosis
Any prior or concurrent primary invasive melanoma mapping to the same draining lymph node basin(s).
Documented history of another (prior or concurrent) primary invasive melanoma of T1b or greater at any site within the last 5 years.
Previous surgery in or radiation therapy to the draining lymph node basin(s) of the current primary melanoma.
Ocular, vulvar, perianal or mucosal melanomas or melanocytic tumors of uncertain malignant potential (MELTUMP) or atypical Spitz tumors.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 9 Locations for this study
Tampa Florida, 33612, United States More Info
Atlanta Georgia, 30322, United States More Info
Lexington Kentucky, 40506, United States More Info
Louisville Kentucky, 40292, United States More Info
Ann Arbor Michigan, 48109, United States More Info
Rochester Minnesota, 55905, United States More Info
New York New York, 10065, United States More Info
Durham North Carolina, 27705, United States More Info
Salt Lake City Utah, 84112, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.